

Special Issue

Renal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editors

Renal cell carcinoma is a complex disease comprised of a variety of histological subtypes. A large number of biomarkers have been proposed for predicting RCC recurrence. Some molecular-targeted therapies, such as tyrosine kinase inhibitors, mTOR inhibitors, and immunotherapies, have dramatically improved the outcome of RCCs. The medical treatment of RCC has greatly changed in recent years, thanks to new information acquired on the molecular pathogenesis and of its histology. However, acquired drug resistance and treatment for a prognostically unfavorable subgroup of ccRCCs and other histological subtypes remain a major challenge. Novel biomarkers to predict outcomes, drug responses, and a novel therapeutic target are highly desirable.

This Special Issue of *Biomedicines* focuses on recent discoveries on clinicopathological, physiological, and molecular approaches to the diagnosis, classification, and novel multidisciplinary treatment. Considering the complexity of the molecular biological background of each histological subtype of renal cell carcinoma, we welcome contributions aimed at both major and emerging histological subtypes of renal cell carcinoma.

Guest Editors

Dr. Silvio Maringhini

Department of Pediatrics, ISMETT, Palermo, Italy

Dr. Riuko Ohashi

Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan

Deadline for manuscript submissions

closed (30 April 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/90141

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).